Corentec America, Inc. a wholly owned subsidiary of Seoul-based Corentec Co., Ltd., has received FDA clearance to market its Lospa Knee System in the United States. The Knee Joint Replacement System is available now, along with the company’s currently available Total Hip Replacement System, and a Pedicle Screw System for spine.
Here Come the Koreans! Top Quality, Better Price
1 min read Premium comments
Secondary
“Corentec America has successfully completed a number of cases in the U.S. using the Lospa Knee System, ” said Michael Y. Son, vice president, Corentec America in a September 13 news release. “The feedback from leading surgeons has been outstanding, exactly as we expected. Surgeons have commented on the positive attributes of the Lospa Knee System, including the wide range of options allowing for patient variables, and in particular, surgeons have made affirmative comments as to the ease-of-use, and intuitiveness of our instrumentation.”
The implants are manufactured in South Korea. Company officials state that the Lospa Knee System offers an anatomically featured shape for both a cruciate retaining (CR) and a posterior stabilized (PS) knee within a single system. This, they say, ensures successful patient outcomes with natural knee range of motion and increased longevity of the implant.
Corentec plans to unveil the Lospa Knee System, and the company’s portfolio of Hip and Knee Joint Implants at the North American Spine Society (NASS) Annual Meeting in Dallas, October 24-27 and at the American Association of Hip and Knee Surgeons (AAHKS) Meeting, in Dallas, November 2-4, 2012, as well as at the American Academy of Orthopaedic Surgeons Meeting, in Chicago, March 19-23, 2013.
“Corentec is continuing its program to establish a network of highly successful distributors who possess deep relationships with leading surgeons, ” said Son. “As we move forward with distribution of Corentec’s advanced solutions for Knee, Hip, and Spine, we will be offering highly competitive commission rates to high-producing distributors throughout the U.S.” Dr. Doo Hoon Sun founded Corentec Co., Ltd., in 2000. The American subsidiary is located in Irvine, California.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.